USPTO serial 97931030
AEST-ETHICA
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- EULIN, INGRID C
- Law office
- TMEG LAW OFFICE 105 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with AEST-ETHICA?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Kirkland, Quebec, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alan S. Nemes
Alan S. Nemes HUSCH BLACKWELL LLP8001 FORSYTH BLVD., SUITE 1500ST. LOUIS, MO 63105UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Contract research services for clinical trials, namely, recruiting investigators, providing strategies for recruitment of participants, screening participants; clinical trial management services, namely, : pre-study document collection and review, site selection, pre-study site visits, initiation visits, monitoring visits, closeout visits, project tracking and monitoring reports, negotiation and administration of investigator grants, labelling, packaging, distribution, coordination and tracking of clinical trial materials, regulatory document processing, central laboratory selection and coordination; clinical trial management services, namely, site and study-specific participant recruitment strategies and programs, namely, contingency strategies and solutions to address specific project challenges, development of all study related documents and materials, namely, study protocols, amendments, case report forms (paper or electronic), informed consent forms, study operations/monitoring manuals in accordance with data management conventions, web-based data listings, namely, adverse events, enrollment status, efficacy endpoints, study newsletters (paper or electronic); management of tracking tools for enrollment, essential documents, monitoring, subject and case report form tracking, drug accountability, data queries, adverse events; clinical trial supplies management services, namely,: customized drug packaging and labelling, randomization (central and site administered) and study supply distribution, developing and managing distribution and storage logistics for all clinical supplies (study drugs and devices, case report forms, study binders, all study related documentation); managing all aspects of study drug reconciliation and inventory and distribution reports; data management services (eCRF Data Fields, eCRF builds, data management plans, database lock, data visualization); Biostatistics services (statistical analysis plans, statistical programming/testing/validation, statistical reports); medical writing services (full integrated clinical research reports, publications, abstracts and manuscripts) | ACTIVE | — |
| 041 | Contract research services for clinical trials, namely, conducting investigator meetings; clinical trial management services, namely, study-specific clinical personnel training programs for investigators and coordinators, investigator meetings | ACTIVE | — |
| 042 | Contract research services for clinical trials, namely, developing study protocols, designing case report forms; developing complete databases in accordance with strict guidelines, cordinating ethics review submissions, developing and maintaining trial master file (paper or electronic), tracking of study parameters, providing statistical analyses and reporting; development of tracking tools for enrollment, essential documents, monitoring, subject and case report form tracking, drug accountability, data queries, adverse events; developing and managing randomization logistics, namely, randomization envelopes, customized blind breakable drug labelling, code break management and reports, manufacturing of subject- and protocol specific kits using bulk oral and topical medications; drafting clinical study protocols, eCRF Data Fields, eCRF builds, data management plans, database lock, data visualization, statistical analysis plans, statistical reports, full integrated clinical research reports, publications, abstracts and manuscripts | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 22, 2024 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 22, 2024 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Feb 6, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 6, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 30, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 30, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 30, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 10, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 15, 2023 | NWAP | NEW APPLICATION ENTERED | — |